Ropidoxuridine
- Generic Name
- Ropidoxuridine
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C9H11IN2O4
- CAS Number
- 93265-81-7
- Unique Ingredient Identifier
- 3HX21A3SQF
- Background
Ropidoxuridine is a novel, orally available, thymidine analogue and prodrug for IUdR, which demonstrated a survival advantage in Phase II studies in anaplastic astrocytoma, a type of brain tumor.
- Indication
Investigated for use/treatment in cancer/tumors (unspecified).
- Associated Conditions
- -
- Associated Therapies
- -
Testing the Addition of a Radiation Sensitizing Drug, IPdR, to the Usual Chemotherapy Treatment (Capecitabine) During Radiation Therapy for Rectal Cancer
- Conditions
- Locally Advanced Rectal CarcinomaRectal AdenocarcinomaStage II Rectal Cancer AJCC v8Stage III Rectal Cancer AJCC v8
- Interventions
- First Posted Date
- 2020-05-29
- Last Posted Date
- 2023-10-05
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 1
- Registration Number
- NCT04406857
- Locations
- ๐บ๐ธ
USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States
๐บ๐ธLos Angeles County-USC Medical Center, Los Angeles, California, United States
๐บ๐ธUniversity of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States
Ropidoxuridine and Whole Brain Radiation Therapy in Treating Patients With Brain Metastases
- Conditions
- Malignant Solid NeoplasmMetastatic Malignant Neoplasm in the BrainHematopoietic and Lymphoid Cell Neoplasm
- Interventions
- Other: Laboratory Biomarker AnalysisOther: Pharmacological StudyOther: Quality-of-Life AssessmentDrug: RopidoxuridineRadiation: Whole-Brain Radiotherapy
- First Posted Date
- 2016-12-15
- Last Posted Date
- 2024-10-30
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 11
- Registration Number
- NCT02993146
- Locations
- ๐บ๐ธ
UT Southwestern/Simmons Cancer Center-Dallas, Dallas, Texas, United States
๐บ๐ธNYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York, New York, United States
๐บ๐ธUniversity of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States
Ropidoxuridine in Treating Patients With Advanced Gastrointestinal Cancer Undergoing Radiation Therapy
- Conditions
- Advanced Bile Duct CarcinomaStage IIB Pancreatic Cancer AJCC v6 and v7Stage II Esophageal Cancer AJCC v7Stage II Pancreatic Cancer AJCC v6 and v7Stage IIA Esophageal Cancer AJCC v7Stage IIA Pancreatic Cancer AJCC v6 and v7Stage IIB Esophageal Cancer AJCC v7Stage III Colon Cancer AJCC v7Stage III Gastric Cancer AJCC v7Stage III Liver Cancer
- Interventions
- Radiation: Intensity-Modulated Radiation TherapyOther: Laboratory Biomarker AnalysisOther: Pharmacological StudyDrug: Ropidoxuridine
- First Posted Date
- 2015-03-06
- Last Posted Date
- 2024-03-07
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 19
- Registration Number
- NCT02381561
- Locations
- ๐บ๐ธ
Rhode Island Hospital, Providence, Rhode Island, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.